Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics is a promising company in the biopharmaceutical industry, with a strong drug candidate in cadisegliatin addressing an unmet need in Type 1 diabetes and potentially expanding its market to Type 2 diabetes. The company's partnerships and other drugs in development show potential for future growth and revenue. However, there are risks and competition that should be considered. With a strong drug profile and potential for revenue growth, vTv Therapeutics has a positive outlook for sustainable success in the treatment of chronic diseases.

Bears say

vTv Therapeutics is heavily focused on developing oral, small-molecule drug candidates, but their current lead candidate, cadisegliatin, has a high risk of failure and limited differentiation from other approved treatments for type 1 diabetes, especially considering the complex and competitive landscape in diabetes treatments. Additionally, vTv's financials show a high reliance on external partnerships and funding to advance their pipeline, adding further risk to their outlook. Overall, the combination of clinical and financial risks make vTv Therapeutics' stock a risky investment.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.